JP2024525188A5 - - Google Patents

Info

Publication number
JP2024525188A5
JP2024525188A5 JP2023577995A JP2023577995A JP2024525188A5 JP 2024525188 A5 JP2024525188 A5 JP 2024525188A5 JP 2023577995 A JP2023577995 A JP 2023577995A JP 2023577995 A JP2023577995 A JP 2023577995A JP 2024525188 A5 JP2024525188 A5 JP 2024525188A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence described
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034189 external-priority patent/WO2022266540A2/en
Publication of JP2024525188A publication Critical patent/JP2024525188A/ja
Publication of JP2024525188A5 publication Critical patent/JP2024525188A5/ja
Pending legal-status Critical Current

Links

JP2023577995A 2021-06-18 2022-06-20 ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法 Pending JP2024525188A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163212414P 2021-06-18 2021-06-18
US63/212,414 2021-06-18
PCT/US2022/034189 WO2022266540A2 (en) 2021-06-18 2022-06-20 ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE

Publications (2)

Publication Number Publication Date
JP2024525188A JP2024525188A (ja) 2024-07-10
JP2024525188A5 true JP2024525188A5 (https=) 2025-06-27

Family

ID=84526541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577995A Pending JP2024525188A (ja) 2021-06-18 2022-06-20 ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法

Country Status (8)

Country Link
US (2) US20240279321A1 (https=)
EP (1) EP4355773A4 (https=)
JP (1) JP2024525188A (https=)
KR (1) KR20240049265A (https=)
CN (1) CN117794948A (https=)
AU (1) AU2022294106A1 (https=)
CA (1) CA3222880A1 (https=)
WO (1) WO2022266540A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2025212751A1 (en) * 2024-04-02 2025-10-09 Therini Bio, Inc. Multi-specific antigen-binding proteins which bind human fibrin yc or fibrinogen yc domain and vascular endothelial growth factor and methods of use
WO2025231345A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases
WO2025231343A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for neurodegenerative diseases

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
HUE031571T2 (en) * 2009-10-02 2017-07-28 Univ California Monoclonal antibodies
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
JP7010854B2 (ja) * 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
CR20190550A (es) * 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso

Similar Documents

Publication Publication Date Title
JP2024525188A5 (https=)
JP7586833B2 (ja) 抗ＩｇＥ抗体
JP7789236B2 (ja) Ｆｃｒｎ／ｈｓａ結合分子及び使用方法
AU2016200412A1 (en) Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
JP2024522237A5 (https=)
EP3180358B1 (en) Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor
JP7490025B2 (ja) Ｃｄ２００ｒアゴニスト抗体およびそれらの使用
JP2025026957A (ja) ＩＬ－１β受容体シグナル伝達に干渉する剤
US20260028396A1 (en) Anti-myostatin antibodies and methods
WO2026064551A2 (en) Methods of use for interleukin-4 receptor alpha antibodies
EA049400B1 (ru) Антитела к ige
HK40058421A (en) Anti-ige antibodies
Presta et al. Understanding the Binding of IgE to Its High-Affinity Receptor and to an Anti-IgE Antibody
EA048233B1 (ru) Агонистические антитела к cd200r и их применение